Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Guardado en:
Autores principales: | Berkay Ekici, Mehmet Yaman, Murathan Küçük, Seçkin Dereli, Mustafa Yenerçağ, Zerrin Yiğit, Mehmet Memduh Baş, Yusuf Karavelioğlu, Hüseyin Altuğ Çakmak, Tarık Kıvrak, Hakan Özkan, Cihan Altın, Cengiz Şabanoğlu, Burcu Demirkan, Ali Ekber Ataş, Fethi Kılıçaslan, Hakan Altay, İstemihan Tengiz, Aycan Fahri Erkan, Barış Kılıçaslan, Fatih Erkam Olgun, Murtaza Emre Durakoğlugil, Aslıhan Alhan, Mehdi Zoghi |
---|---|
Formato: | article |
Lenguaje: | EN TR |
Publicado: |
KARE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5aa0136efcca4d2285e92d2abb9da18c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and effectiveness of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure with preserved ejection fraction (HFPEF) – ‘ARNI-preserved’ study
por: Pankaj Jariwala, et al.
Publicado: (2021) -
ARNI, LBBB, COVID-19 and various other topics
por: Çetin Erol
Publicado: (2021) -
Neprilysin as a Biomarker: Challenges and Opportunities
por: Noemi Pavo, et al.
Publicado: (2020) -
Relevance of Neutrophil Neprilysin in Heart Failure
por: Suriya Prausmüller, et al.
Publicado: (2021) -
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
por: Ferhat Dindaş, et al.
Publicado: (2021)